RELATED CONTENT
NEWS
- 2011 US submission for Genentech/Curis' vismodegib in basal cell carcinoma
- Positive Phase III data for LifeCycle's 'improved Prograf' despite higher drop-out
- UK govt offers "step change" in support for regenerative medicine
- Gilenya and Tasigna drive new product growth at Novartis

